United States: Capitol Hill Healthcare Update - January 18, 2017

The House on Friday gave final congressional approval to a budget blueprint that authorizes separate filibuster-proof legislation Republicans will use next month to repeal much of the Affordable Care Act (ACA).

Republican-led committees in the House and Senate now will begin drafting the so-called reconciliation legislation that will repeal portions of the health law. Lawmakers hope to have that bill ready to send to the White House before the end of February.

Republican leaders want to see the ACA repeal bill also include significant replacement provisions. Complicating efforts for Republicans is that only language changing government spending or revenue qualifies to be included in a reconciliation bill, which Senate Democrats can't block with a filibuster. If Republicans try to test those rules, the Senate parliamentarian, Elizabeth MacDonough, could overrule them.

After approving the reconciliation bill with both significant repeal and replace provisions, Republicans say they will turn their attention to pushing a series of stand-alone bills that would collectively form the balance of their replacement health plan. Unlike the reconciliation legislation, those individual bills could be stopped by Senate Democrats, but Republicans believe they can lure enough Democrats to support the individual replacement bills to shut down filibusters.

Republicans expect to flesh out their plans next week in Philadelphia, where the House and Senate GOP will be holding an annual retreat.

Trump doubles down on drug prices

President-elect Donald Trump shows no signs of backing away from statements he first made last year about cracking down on pharmaceutical manufacturers over drug prices, and his rhetoric may resonate with a surprising number of Republican lawmakers.

During a news conference last week and a media interview this weekend, Trump criticized pharma companies for leaving the United States, making drugs overseas and "getting away with murder." He also said the federal government should be directly negotiating drug prices.

Sparking a populist fight with drug companies may find traction for Trump on Capitol Hill, where the industry's influence has waned in recent years after significant turnover among lawmakers. Medicare's Part D prescription drug benefit, which a Republican-controlled Congress passed in 2003, likely couldn't win approval in the current GOP Congress (indeed, Vice President-elect Pence voted against creating Part D when he served in the House).

Last week 10 Senate Republicans – including a member of the GOP leadership, Sen. John Thune (R-S.D.); conservatives Sens. Ted Cruz (R-Texas) and Mike Lee (R-Utah); moderate Sen. Susan Collins (R-Maine); and two committee chairmen, Sens. John McCain (R-Ariz.) and Chuck Grassley (R-Iowa) – voted to allow prescription drugs to be imported from Canada – a policy long opposed by pharma companies. The drug importation vote ultimately failed as seven Senate Democrats broke with their party to block the effort.

Brady says GOP will repeal ACA taxes "immediately"

House Ways and Means Committee Chairman Kevin Brady (R-Texas) told reporters publicly and stakeholders privately last week that Congress will repeal the ACA's tax provisions this year.

Some Republicans had speculated the taxes could stay in place at least during the transition period or to finance whatever replacement plan GOP leaders develop. But Brady shot that down last week, pledging that ACA taxes would be repealed immediately.

The ACA's Cadillac tax on high-cost health plans already had been pushed back to 2020, and the 2.3 percent excise tax on medical devices is entering the last year of a two-year suspension. Other taxes and fees on pharmaceutical manufacturers and upper-income taxpayers are in effect.

Price's confirmation hearings begin Wednesday

The Senate HELP Committee this week will kick off confirmation hearings for Trump's nominee to be Secretary of the U.S. Department of Health and Human Services (HHS), but Rep. Tom Price (R-Ga.) likely won't be confirmed until next month.

Committee Chairman Lamar Alexander (R-Tenn.) said his panel will hold a hearing on Price's nomination Wednesday. The Senate Finance Committee, which has primary jurisdiction over HHS nominees, will hold a separate hearing later this month.

The timing could be important because Trump has said he would announce his plans to replace the ACA only after Price is confirmed.

Although several Senate Democrats have come out against Price, he's currently expected to win confirmation.

User fee hearings may start in February

Hearings on the FDA user fees negotiated with pharmaceutical and medical device manufacturers are expected to begin in the House next month.

The House Energy and Commerce Committee could hold hearings as early as next month on the separate user fee agreements for manufacturers of brand and generic drugs, biologics, and medical technology. The House hopes to complete consideration by early this summer.

The Senate is on a slower track because the Senate HELP Committee is currently focused on confirmation hearings for Trump's incoming cabinet secretaries and senior officials. HELP Committee hearings on the user fees aren't expected to get underway until March.

Although the current user fee authorization won't expire until Sept. 30, lawmakers want to finish consideration of the new agreements by this summer, ahead of a mandated deadline when layoff warnings would have to be distributed to FDA employees. Both committees also say they want to keep the agreements free from other provisions, like efforts to reduce drug prices.

House OKs public health bills

The House last week approved four bipartisan public health bills, including one that would establish a national commission to recommend coordinated care for patients of metabolic syndromes and related autoimmune disorders.

The House also approved legislation that would increase HHS data collection to disperse maternal health professionals in rural and underserved communities. That legislation was introduced by House Energy and Commerce Health Subcommittee Chairman Michael Burgess (R-Texas).

Other legislation that won House approval would ensure sports medicine professionals are covered by their malpractice insurance when providing care to athletes or teams in other states, and legislation streamlining the Drug Enforcement Administration registration process for emergency medical services and permitting EMS professionals to administer controlled substances.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.